Develops innovative therapies using biotechnology to address a variety of serious medical conditions.
Barinthus Biotherapeutics plc is a dynamic clinical-stage biopharmaceutical company focused on advancing novel T cell immunotherapeutic candidates aimed at combating chronic infectious diseases, autoimmunity, and cancer. Established with a strong commitment to innovation, Barinthus Biotherapeutics leverages its expertise to develop transformative treatments that harness the immune system's potential.
The company's robust development pipeline includes several promising candidates. Among these, VTP-300 is undergoing Phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection. VTP-200, another Phase 2 candidate, targets persistent high-risk human papillomavirus (HPV) infection without the need for surgery. Barinthus Biotherapeutics is also advancing VTP-1000, a preclinical candidate for autoimmune diseases like celiac disease, and VTP-1100 to combat HPV16+ cancers. Additionally, VTP-850/850, a second-generation immunotherapeutic candidate, is in Phase 2 trials for recurrent prostate cancer.
In collaboration efforts, Barinthus Biotherapeutics is involved in developing partnered candidates like AB-729-202, currently in Phase 2a trials for chronic HBV infection. Other initiatives include VTP-600, a Phase 1 immunotherapy candidate for non-small cell lung cancer (NSCLC) in combination with standard treatments, and VTP-500, a Phase 1 prophylactic vaccine candidate targeting the MERS coronavirus. Furthermore, the company is advancing VTP-400, a Phase 1 prophylactic vaccine to prevent shingles in adults aged 50 years and older. Notably, Barinthus Biotherapeutics also offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine approved for the prevention of COVID-19 infection.
Driven by innovation and a commitment to improving global health outcomes, Barinthus Biotherapeutics plc continues to expand its portfolio and advance cutting-edge therapies through strategic partnerships and rigorous clinical development efforts. The company's dedication to transformative immunotherapy underscores its mission to address significant medical challenges and improve the lives of patients worldwide.